ZCG Announces Partnership With Scuderia Ferrari for 2023 Formula 1 Season
Z Capital Group, L.L.C. ("ZCG") today announced it has signed as a Team Partner to Scuderia Ferrari for the 2023 season. Through this partnership, ZCG’s logo will appear on the SF-23 livery starting at the Bahrain Grand Prix, the first round of the 2023 Formula 1 World Championship.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005697/en/
Z Capital Group announced it has signed as a Team Partner to Scuderia Ferrari for the 2023 season (Graphic: Business Wire)
“ZCG shares Scuderia Ferrari’s steadfast commitment to innovation and excellence,” said James Zenni, Founder, President and Chief Executive Officer of ZCG. “This is a unique opportunity to partner with one of the sport’s most iconic brands and to engage with millions of fans and Formula 1 enthusiasts around the world. Ferrari has been a central player throughout Formula 1’s long and storied history. We are thrilled to support the team as it enters the 2023 season in pursuit of its record 17th championship.”
“Operating at the highest level in the world of motorsport we are always looking for partners who share our global perspective and dedication to unparalleled performance,” said Lorenzo Giorgetti, Chief Racing Revenue Officer of Scuderia Ferrari. “We are pleased to welcome ZCG as a Team Partner and can’t wait to build on this partnership together in the year ahead.”
Formula 1, already one of the most exciting and prestigious motorsport competitions in the world, has experienced a surge in popularity in recent years. In the United States alone, the 2022 season averaged nearly 300,000 more viewers across each of its 22 Grand Prix weekends than the prior season. As Formula 1 continues to grow in popularity across the globe, this partnership will align ZCG with one of the sport’s most storied names.
2023 will be ZCG’s second year supporting the growth of Formula 1 as a Team Partner and its first year working with Scuderia Ferrari.
About ZCG
ZCG is an industry leader comprised of private markets asset management, business consulting services, technology development and solutions.
For almost 30 years, ZCG Principals have invested approximately $30 billion and have industry leading track records in private equity and credit.
ZCG has approximately $6.5B of AUM in asset management and its investors are some of the largest and most sophisticated global institutional investors including pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies.
ZCG has a global team comprised of nearly 400 professionals. For more information, please visit www.zcg.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005697/en/
Contact information
Media
Tim Ragones / Kate Thompson / Erik Carlson
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO ® (avelumab)27.3.2023 14:00:00 CEST | Press release
Merck today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of their Alliance agreement with Pfizer. “On behalf of Merck, I’d like to thank Pfizer for their partnership and collaboration over the last nine years, and for the role they have played in the success of BAVENCIO,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “Our joint efforts have delivered meaningful therapeutic value to patients around the world who are living with cancer. This has been an incredible journey for us, and thanks to Pfizer’s partnership we are now very well positioned to continue to deliver this therapy to patients in need.” “Our alliance with Merck allowed us to combine our complementary strengths to develop and launch BAVENCIO to help meet the needs of people with cancer globally,” said Dr. Albert Bourla,
Ecoppia Expands its Global Presence with 4 New Projects in Spain and Chile with Matrix Renewables27.3.2023 14:00:00 CEST | Press release
Ecoppia, world’s leader in robotic cleaning solutions has announced an agreement to deploy its robotic solutions in 4 projects developed by Matrix Renewables, the TPG Rise-backed global renewable energy platform. This collaboration will mark Ecoppia’s first project in the Spanish region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005227/en/ Ecoppia H4 Autonomous Robotic Cleaning Solution (Photo: Business Wire) Ecoppia will deploy two robotic models at these PV sites – the Ecoppia H4 and the Ecoppia T4. Both robots are water-free and perform highly efficient cleaning while proven to be fully safe on the modules and structure. Ecoppia will also provide the operations and maintenance (O&M) to the robotics fleet for the projects’ lifetime. The expected total revenues from these projects during their lifespan is estimated at around $13M USD, of which $3.9M against the systems delivery and installation. This announcement
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes27.3.2023 14:00:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230324005339/en/ “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinical development,” said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. “Having successfully demonstrated clinical proof of concept in T1D in our VX-880 program, we are excited to deepen our relationship with CRISPR Therapeutics with this agreement, which will allow us to further accelerate our goal of generating fully dif
Enviva Issues Statement Following Destructive Storms and Tornadoes in Mississippi27.3.2023 13:00:00 CEST | Press release
Enviva Inc. (NYSE: EVA) (“Enviva,” the “Company,” “we,” “us,” or “our”), the world’s leading producer of sustainably sourced woody biomass, reported that all of its associates are safe and accounted for following a strong tornado that touched down in Amory, Mississippi, on March 24, 2023. The storm did, however, damage the Company’s 115,000 metric ton per year wood pellet production facility, although Enviva’s larger plants and ports in the region were not impacted. Enviva’s Amory facility insurance covers property damage, inclusive of business interruption and casualty. Operations at the plant have been suspended pending a full review of the damage, but given the small size of the facility relative to the more than six million metric tons of installed production capacity across the Company’s portfolio, the impact to customers and to the financial performance of the Company is expected to be minimal. “Amory was our very first plant in the Southeast U.S. and this community holds a speci
Li-Cycle and KION Group Form Strategic Global Lithium-Ion Battery Recycling Partnership; Li-Cycle Announces New Spoke Development in France27.3.2023 12:00:00 CEST | Press release
Li-Cycle Holdings Corp. (NYSE: LICY) (“Li-Cycle” or the “Company”), an industry leader in lithium-ion battery resource recovery and the leading lithium-ion battery recycler in North America, has signed a definitive agreement (“agreement”) for a global lithium-ion battery recycling partnership with the KION Group (“KION”), a leading global provider of industrial trucks and supply chain solutions. The Company is also pleased to announce plans to develop a new lithium-ion battery recycling facility in France, underpinned by regional commercial demand, including KION’s lithium-ion battery recycling needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005333/en/ Strategic Partnership for sustainable circular economy: Andreas Krinninger, member of the Executive Board of KION GROUP AG, and Elewout Depicker, VP Commercial and Corporate Development EMEA of Li-Cycle Corp. will be working together in future on the recycling of l